ANANDA Scientific and the David Geffen School of Medicine, UCLA, Announce Commencement of a Clinical Trial Evaluating Nantheia™ ATL5 for Smoking Cessation

Contributed by: Business Wire

Logo

Images

(Photo: Business Wire)

Business Wire embedded0

Tags

Research

Neurology

Cannabis

Clinical Trials

Biotechnology

Health

Pharmaceutical

Science

Natural Resources

Nantheia ATL5 for Smoking Cessation

More Like This

(Photo: Business Wire)

ANANDA Scientific Announces a Clinical Trial Evaluating Nantheia™ ATL5, in the treatment of Co-Occurring Opioid Use Disorder and Chronic Pain

Tilray Medical Announces Positive Results from Study on Oral Cannabis Extract for Chemotherapy-Induced Emesis

CBD is approved for treatment-resistant epilepsy in children, and recent trials suggest that it may be useful for treating other disorders, such as schizophrenia and anxiety. Photo credit: Julia Zolotova

Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases

Avata Biosciences Emerges to Develop Solid Dose Cannabinoid Medicines for Epilepsy and Other Neurological Diseases

Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Tilray Medical Supports New Clinical Trial to Study Medical Cannabis in Glioblastoma Cancer Treatment

First Cannabis full-spectrum product, manufactured in Brazil by Ease Labs, is approved by the local Health Regulatory Agency